6533b860fe1ef96bd12c3c37

RESEARCH PRODUCT

Immunogenicity of reduced antigen content tetanus–diphtheria–acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine

Fred ZeppLeonard R. FriedlandP. HabermehlWilma Mannhardt-laakmanMarkus KnufBarbara Howe

subject

MaleTime FactorsWhooping CoughHepatitis A vaccineImmunization SecondaryBooster doseDiphtheria-Tetanus-acellular Pertussis Vaccinescomplex mixturesDouble-Blind MethodmedicineHumansChildWhooping coughAntigens BacterialHepatitis A VaccinesTetanusGeneral VeterinaryGeneral Immunology and MicrobiologyTetanusbusiness.industryImmunogenicityDiphtheriaPublic Health Environmental and Occupational HealthDiphtheriamedicine.diseaseAntibodies BacterialVaccinationInfectious DiseasesImmunizationImmunologyMolecular MedicineFemalebusiness

description

Three hundred and nineteen adolescents aged 10-12 years who had been previously vaccinated with five doses of acellular pertussis-containing vaccines received single doses of Tdap (reduced-antigen-content tetanus, diphtheria, acellular pertussis) and hepatitis A vaccines in a double-blind crossover trial. Long-term antibody persistence following vaccination with Tdap at pre-school age was similar to that following vaccination with DTaP (diphtheria-tetanus-acellular pertussis). After the sixth dose booster, Tdap induced a vigorous immune response, consistent with protection against diphtheria, tetanus and pertussis diseases.

yearjournalcountryeditionlanguage
2006-10-18Vaccine
https://doi.org/10.1016/j.vaccine.2007.05.012